Sanofi India Limited , a prominent player in the pharmaceutical sector, has released its financial results for the third quarter ended September 30. The company demonstrated mixed performance, with improved profitability margins despite a decline in revenue and net profit.

Financial Highlights

Key Takeaways

1. Revenue Decline: Sanofi India experienced a year-over-year decrease in revenue from ₹524.00 crore to ₹475.40 crore, representing a decline of 9.30%.

2. Improved EBITDA: Despite the revenue drop, the company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased from ₹120.00 crore to ₹134.00 crore, showing a growth of 11.67%.

3. EBITDA Margin Expansion: The EBITDA margin saw a significant improvement, rising from 23.00% to 28.00%, indicating enhanced operational efficiency.

4. Net Profit Decrease: The company's net profit declined from ₹82.00 crore to ₹76.00 crore, a decrease of 7.32% compared to the same quarter last year.

Corporate Actions and Strategy

1. Interim Dividend: The Board declared an interim dividend of ₹75 per equity share. The record date for this dividend is set for November 7.

2. Portfolio Streamlining: Sanofi India is focusing on streamlining its portfolio to concentrate on core therapeutic areas, including diabetes and cardiovascular treatments.

3. Cost Efficiency: The company's improved EBITDA and operating margin are attributed to cost efficiency measures and a favorable product mix.

Market Performance

Following the results announcement, Sanofi India's shares remained largely unchanged at ₹4,747.00. The stock has gained 22% year-to-date, indicating overall positive investor sentiment despite the mixed quarterly results.

The mixed results reflect the challenging environment in which Sanofi India operates. While the company has managed to improve its operational efficiency, as evidenced by the higher EBITDA and margin, the decline in revenue and net profit indicates ongoing market pressures.

Investors and stakeholders will likely be watching closely to see how Sanofi India's strategic moves, such as portfolio streamlining and cost efficiency measures, will impact its performance in the coming quarters. The company's ability to maintain its improved margins while addressing the revenue decline will be crucial for its future financial health.

Sanofi India Limited has successfully completed the shareholder approval process for Deepak Arora's appointment as Managing Director, with the postal ballot concluding on December 17, 2025. The voting results demonstrate strong shareholder confidence in the new leadership appointment.

Shareholder Approval Results

The postal ballot voting, conducted through remote e-voting from November 18 to December 17, 2025, yielded decisive results for both resolutions. The scrutinizer's report, prepared by Gaurav Sainani of SGGS Associates, confirmed the approval of Deepak Arora's dual appointment.

Voting Process and Compliance

The postal ballot process was conducted in full compliance with Regulation 44 of SEBI Listing Regulations and the Companies Act, 2013. The cut-off date for eligible voters was November 14, 2025, and the notice was dispatched to shareholders via email on November 17, 2025.

New Leadership at the Helm

Deepak Arora's appointment as Managing Director, effective from October 27, 2025, brings over three decades of pharmaceutical and healthcare experience to Sanofi India. His career spans across various geographies including North America, Europe, Middle East, and Africa, where he has held leadership positions in commercial, sales, marketing, and general management roles.

Key Responsibilities and Strategic Vision

In his new position, Arora will be tasked with defining and driving the strategic vision for Sanofi in India, spearheading strategic priorities to boost innovation and agility, fostering operational excellence across all functions, and championing the company's Diversity, Equity, and Inclusion culture.

Management Transition Details

Rachid Ayari stepped down from his position as Interim Managing Director on October 26, 2025, after serving in the interim role since July 21, 2025. Ayari continues to serve as Whole-time Director and Chief Financial Officer of Sanofi India. The Board has also authorized Deepak Arora to determine the materiality of events and make stock exchange disclosures, alongside other Key Managerial Personnel.

This management change, now formally approved by shareholders, marks a new chapter for Sanofi India as it continues its mission to promote health and chase the miracles of science to improve people's lives across the entire health spectrum in India.